Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
J Cosmet Dermatol ; 21(9): 3655-3662, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-1922985

ABSTRACT

OBJECTIVE: While there are literature reporting increased incidence of hair loss in COVID-19 patients, insufficient evidence exists on the topic to date. This review aims to identify the existing evidence and clinical characteristics of hair loss with COVID-19 infection. METHODS: Following the PRISMA Extension for Scoping Reviews, MEDLINE and EMBASE were searched for all peer-reviewed articles with relevant keywords including "Alopecia," "Telogen Effluvium (TE)," and "COVID-19" from their inception to November 20, 2021. RESULTS: A total of 26 articles, with 9 observational studies and 17 case reports or series (a total of 58 cases), were included. Most studies dealt with TE. There were no clear trends between COVID-19 severity and the extent of hair loss. Analysis of the 58 cases also found similar results with most of the cases being female (82.8%), the median onset of hair loss of 2.0 months, and the median time to recovery of hair loss of 5.0 months with a resolution rate of 95%. CONCLUSION: While this systematic review revealed uncertainty and a lack of strong evidence regarding the association of COVID-19 and hair loss, hair loss in COVID-19 may mainly include TE and be reversible in nature. Future studies are warranted to determine the detailed pathophysiology and risk factors of hair loss in COVID-19, including possible roles of estrogen, progesterone, and pro-inflammatory cytokines.


Subject(s)
Alopecia Areata , COVID-19 , Alopecia/complications , Alopecia/etiology , Alopecia Areata/etiology , COVID-19/complications , COVID-19/epidemiology , Cytokines , Estrogens , Female , Humans , Male , Progesterone
3.
J Cosmet Dermatol ; 21(9): 3675-3678, 2022 09.
Article in English | MEDLINE | ID: covidwho-1909445
4.
Dermatol Ther ; 35(7): e15545, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1819890

ABSTRACT

The clinical presentation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2 COVID-19) varies from asymptomatic infection to a life-threatening, multiorgan disease. One of these manifestations is telogen effluvium (TE) which is characterized by diffuse hair loss occurring in patients previously infected with SARS-CoV-2 and lasts ~3 months, after which excessive hair loss follows. Hair follicles are known to contain a well-characterized niche for adult stem cells which is the bulge containing epithelial and melanocytic stem cells. Stem cells in the hair bulge, a demarcated structure within the lower permanent portion of hair follicles, can generate the interfollicular epidermis, hair follicle structures, and sebaceous glands. This study aims to evaluate autologous micrografts from scalp tissues as a therapeutic modality in the management of TE caused by COVID-19. Twenty patients of previous COVID-19 infection suffered from TE were included in this study for human follicle stem cells micrograft scalp treatment and they were evaluated after 3 months of treatment and after 6 months. There was significant improvement of the hair thickness and density compared with the start of the treatment and 6 months of follow-up. Autologous micrograft of the scalp showed marked improvement in the treatment of COVID-19 TE.


Subject(s)
Alopecia Areata , Autografts , COVID-19 , Hair Follicle , Microsurgery , Scalp , Adult , Alopecia Areata/etiology , Alopecia Areata/surgery , Alopecia Areata/virology , COVID-19/complications , COVID-19/virology , Follow-Up Studies , Hair Follicle/transplantation , Humans , SARS-CoV-2 , Scalp/transplantation , Stem Cell Transplantation , Time Factors
5.
J Med Virol ; 94(4): 1391-1401, 2022 04.
Article in English | MEDLINE | ID: covidwho-1718412

ABSTRACT

This systematic review focuses on the clinical features, physical examination findings, outcomes, and underlying pathology of acute telogen effluvium (TE), a type of diffuse hair loss, occurring in coronavirus disease 2019 (COVID-19) recovered patients. MEDLINE/PubMed and Embase databases were queried till October 2021 to identify studies reporting acute TE occurring after COVID-19 recovery. Data were obtained from 19 studies, which included 465 patients who were diagnosed with acute TE. The median age of these patients was 44 years and 67.5% were females. The most common trichoscopic findings were decreased hair density, the presence of empty follicles, or short regrowing hair. The mean duration from COVID-19 symptom onset to the appearance of acute TE was 74 days, which is earlier than classic acute TE. Most patients recovered from hair loss, while a few patients had persistent hair fall. Our results highlight the need to consider the possibility of post-COVID-19 acute TE in patients presenting with hair fall, with a history of COVID-19 infection, in the context of COVID-19 pandemic. Despite being a self-limiting condition, hair loss post-COVID-19 is a stressful manifestation. Identifying COVID-19 infection as a potential cause of acute TE will help the clinicians counsel the patients, relieving them from undue stress.


Subject(s)
Alopecia Areata/etiology , COVID-19/complications , Alopecia Areata/diagnosis , Alopecia Areata/pathology , Alopecia Areata/therapy , COVID-19/diagnosis , COVID-19/pathology , COVID-19/therapy , Dermoscopy , Female , Humans , Male , Middle Aged , SARS-CoV-2 , Treatment Outcome
6.
J Cosmet Dermatol ; 21(4): 1339-1346, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1625816

ABSTRACT

Emerging literature evidence shows that the manifestations of the coronavirus disease 2019 (COVID-19), which is the disease caused by SARS-CoV-2, encompass alterations of the pulmonary, cardiovascular, gastrointestinal, and neurological system. Moreover, hematologic and dermatologic manifestations have been documented. The aim of this review is to summarize the dermatologic manifestations of COVID-19 involving the hair and nails in a narrative way. A total of 1136 patients have been reported to have de novo hair loss following COVID-19. Notably, 958 patients experienced telogen effluvium (TE) (female/male ratio = 3,86:1), two female patients experienced anagen effluvium, and 176 people had alopecia areata (female/male ratio of 19:3). Ten patients were reported to have ungual changes following the infection with the novel coronavirus: The individuals affected were 6 women and 4 men. COVID-19 can be associated with hair and ungual manifestations. This review summarizes the evidence regarding the hair and ungual manifestations of COVID-19, which could be harnessed to better understand the clinical implications and pathophysiology of this disease that has been burdening society globally since December 2019.


Subject(s)
Alopecia Areata , COVID-19 , Alopecia/complications , Alopecia Areata/epidemiology , Alopecia Areata/etiology , COVID-19/complications , Female , Hair , Humans , Male , Nails , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL